Scholarlink

Background <p>Wide antral circumferential ablation (WACA) is considered the gold standard for pulmonary vein isolation (PVI) in atrial fibrillation (AF) ablation. Single shot devices of increasing diameter, delivering both thermal and pulsed field ablation, are being introduced in clinical practice. However, benefit of ablating larger antral areas on long-term efficacy remains unclear.</p> Objective <p>Our trial aims to determine whether ablation of a larger antral area with a larger single-shot ablation device improves rhythm outcomes compared to traditional single-shot PVI.</p> Methods <p>WIDER-PVI is a prospective, multicenter, randomized controlled trial enrolling patients with paroxysmal AF of any duration or persistent AF diagnosed within the two years prior to ablation. Participants are randomized 1:1 to undergo PVI using either a single-shot device with standard (28-mm cryoballoon, control group) or larger (31-mm cryoballoon, experimental group) antral coverage. The dual primary endpoints are [1] freedom from atrial tachyarrhythmia recurrence lasting &gt;30 s at 12 months, and [2] atrial arrhythmia burden, both assessed via wearable or implantable rhythm monitoring systems. Secondary endpoints include acute procedural metrics (procedure duration, left atrial dwell time, fluoroscopy exposure), need for balloon size crossover, recurrence patterns, repeat ablation rates, and cardiovascular events during follow-up. This study has been registered at ClinicalTrials.gov (NCT06698159).</p> Conclusion <p>WIDER-PVI is the first randomized trial to evaluate whether a larger-diameter single-shot device with enhanced antral coverage improves rhythm outcomes compared to standard single-shot PVI. Its findings may guide future ablation strategies, device design, and clinical decision-making in AF treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Wide-Antral pulmonary vein isolation in patients undergoing atrial fibrillation ablation with a Single-Shot technique: rationale and design of the WIDER-PVI trial

  • 期刊论文

  • 发表日期：

    2025年11月6日

查看全文
  • Lucía Cobarro,
  • Martín Negreira-Caamaño,
  • Lorena Gómez-Burgueño,
  • Isabel López-Alacid,
  • Javier Ramos-Jiménez,
  • Álvaro Marco del Castillo,
  • Ez Alddin Rajjoub Al-Mahdi,
  • Luis Borrego-Bernabé,
  • Álvaro Estévez-Paniagua,
  • Serge Boveda,
  • Juan Delgado,
  • Rafael Salguero-Bodes,
  • Fernando Arribas-Ynsaurriaga,
  • Daniel Rodríguez-Muñoz

摘要

Background

Wide antral circumferential ablation (WACA) is considered the gold standard for pulmonary vein isolation (PVI) in atrial fibrillation (AF) ablation. Single shot devices of increasing diameter, delivering both thermal and pulsed field ablation, are being introduced in clinical practice. However, benefit of ablating larger antral areas on long-term efficacy remains unclear.

Objective

Our trial aims to determine whether ablation of a larger antral area with a larger single-shot ablation device improves rhythm outcomes compared to traditional single-shot PVI.

Methods

WIDER-PVI is a prospective, multicenter, randomized controlled trial enrolling patients with paroxysmal AF of any duration or persistent AF diagnosed within the two years prior to ablation. Participants are randomized 1:1 to undergo PVI using either a single-shot device with standard (28-mm cryoballoon, control group) or larger (31-mm cryoballoon, experimental group) antral coverage. The dual primary endpoints are [1] freedom from atrial tachyarrhythmia recurrence lasting >30 s at 12 months, and [2] atrial arrhythmia burden, both assessed via wearable or implantable rhythm monitoring systems. Secondary endpoints include acute procedural metrics (procedure duration, left atrial dwell time, fluoroscopy exposure), need for balloon size crossover, recurrence patterns, repeat ablation rates, and cardiovascular events during follow-up. This study has been registered at ClinicalTrials.gov (NCT06698159).

Conclusion

WIDER-PVI is the first randomized trial to evaluate whether a larger-diameter single-shot device with enhanced antral coverage improves rhythm outcomes compared to standard single-shot PVI. Its findings may guide future ablation strategies, device design, and clinical decision-making in AF treatment.

Graphical Abstract